Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Withdrawn 1Unknown 1Suspended 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 11Lymphoma 11Small Cell Lung Carcinoma 6Lymphoma, Non-Hodgkin 5Lymphoma, Follicular 5Lung Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Carcinoma, Non-Small-Cell Lung 4Burkitt Lymphoma 4Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Sarcoma 2Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Lymphoma, T-Cell, Peripheral 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, AIDS-Related 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Dendritic Cell Sarcoma, Interdigitating 2Unspecified Adult Solid Tumor, Protocol Specific 1Thymoma 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Sezary Syndrome 1

Interventions

Doxorubicin 2tazemetostat 1romidepsin 1pembrolizumab 1etoposide phosphate 1duvelisib 1cc-486 1Vincristine 1Prednisone 1Prednisolone 1Melphalan 1Etoposide 1Cytarabine 1Cyclophosphamide 1Carmustine 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Enteropathy-Associated T-Cell Lymphoma × Etoposide × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡